Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1623 1642 1646
This examiner grants 48% of resolved cases
Mark Halvorson is an examiner in Tech Center 1600, assigned to Art Unit 1623. With 813 resolved cases, there is a significant volume of data to inform prosecution strategies. The examiner's allowance rate is 47.8 percent, which indicates that less than half of the applications result in a patent grant. This 47.8 percent rate suggests a rigorous examination process in Art Unit 1623, where applicants must be prepared for substantive rejections.
The median days to allowance is 1325, pointing to a long duration for successful applications. This 1325-day timeline means that practitioners should expect a multi-year process when seeking an allowance. The data also highlights an interview lift percentage of 20.8. This 20.8 percent lift indicates that interviews are quite effective, providing a substantial boost to the probability of allowance. Given the 47.8 percent baseline allowance rate, the 20.8 percent lift suggests that verbal communication can help bridge gaps in the written record. For those operating in Tech Center 1600, understanding the 1325-day median pendency and the value of interviews is essential for managing client expectations and achieving favorable outcomes.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18933358 | BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS | Non-Final OA | Genentech, Inc. |
| 14701912 | RNA-Guided Human Genome Engineering | Final Rejection | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 14681510 | RNA-Guided Human Genome Engineering | Final Rejection | President and Fellows of Harvard College |
| 14318933 | RNA-Guided Human Genome Engineering | Final Rejection | President and Fellows of Harvard College |
| 17625264 | Methods of Enhancing Immunogenicity of Cancers | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18501865 | CALCIUM VOLTAGE-GATED CHANNEL AUXILIARY SUBUNIT GAMMA 1 (CACNG1) BINDING PROTEINS AND CACNG1-MEDIATED DELIVERY TO SKELETAL MUSCLE | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17734688 | BIOCHEMICAL ASSAYS FOR THERAPEUTIC PROTEINS | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 16094786 | IMPROVED HLA EPITOPE PREDICTION | Final Rejection | The General Hospital Corporation |
| 18062937 | PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY | Final Rejection | The Board of Regents of The University of Texas System |
| 16643607 | Radioluminescent Nanoparticles for Radiation-Triggered Controlled Release Drugs | Final Rejection | PURDUE RESEARCH FOUNDATION |
| 17910637 | A Combined Inhibition of EGFR and NRF2 in The Treatment of Malignant Glioma | Final Rejection | United States Government as represented by the Department of Veterans Affairs |
| 18363747 | SERUM ALBUMIN-BASED FUSION PROTEIN, AND NANO-ASSEMBLY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Non-Final OA | SOUTH CHINA UNIVERSITY OF TECHNOLOGY |
| 18452985 | ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF | Non-Final OA | Compugen Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy